ANIP ANI PHARMACEUTICALS INCcompanySEC Filings & Insider Trading Activity 2026
Latest ANI PHARMACEUTICALS INC (ANIP) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 27, 2026, a 10-Q quarterly report filed on November 7, 2025, an 8-K current report filed on April 7, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for ANI PHARMACEUTICALS INC (ANIP) (SEC CIK 1023024), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: developing, manufacturing, commercializing therapeutics via Rare Disease, Generics, and Brands segments
- • Acquired Alimera Sciences on September 16, 2024, adding ILUVIEN® and YUTIQ® products
Risk Factors
- • Regulatory/legal risk: Compliance with Medicaid Drug Rebate Program risks material penalties due to increased rebate accruals from branded and authorized generic products
- • Geopolitical/macro risk: 17% of raw materials/API from one domestic supplier in 2025; supply disruption risk from FDA inspections and trade or geopolitical tensions
Management Discussion & Analysis
- • Total revenue details not provided for FY 2024; Alimera acquisition adds ILUVIEN® and YUTIQ® franchises
- • No specific operating margin or profitability figures mentioned in the available excerpt
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • NEW risk: acquisition and integration of Alimera Sciences in Sept 2024, expanding product portfolio with ILUVIEN and YUTIQ, adding commercial/regulatory complexity
- • Material update: expanded FDA label for ILUVIEN in Mar 2025 to include chronic NIU-PS, increasing market opportunity and promotional efforts
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Reg FD disclosure signed by CFO Stephen P. Carey on March 3, 2026, indicating material non-public information was selectively shared and is now being publicly disclosed
- • No financial figures or specific disclosure content included in the filing text — full substance contained in referenced exhibit
Item 2.02: Results of Operations and Financial Condition
- • Q4 or full-year results reported by ANI Pharmaceuticals (ANIP), signed February 27, 2026 — refer to accompanying exhibit for key figures
- • CFO Stephen P. Carey authorized the filing; actual financial results contained in the press release exhibit, not the filing body
Annual Reports Archive10-K
AI-powered analysis of ANI PHARMACEUTICALS INC (ANIP) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of ANI PHARMACEUTICALS INC (ANIP) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of ANI PHARMACEUTICALS INC (ANIP) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $316.4M | $486.8M | $614.4M | $883.4M |
| Operating Income | -$35.3M | $47.0M | $584K | $111.1M |
| Net Income | -$47.9M | $18.8M | -$18.5M | $78.3M |
| Op. Margin | -11.2% | 9.6% | 0.1% | 12.6% |
| Net Margin | -15.1% | 3.9% | -3.0% | 8.9% |
| Balance Sheet | ||||
| Total Assets | $760.1M | $904.4M | $1.3B | $1.4B |
| Equity | $313.7M | $432.7M | $403.7M | $540.7M |
| ROE | -15.3% | 4.3% | -4.6% | 14.5% |
Source: XBRL financial data from ANI PHARMACEUTICALS INC (ANIP) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 7, 2026 | — | — | — |
8-K | Mar 3, 2026 | — | Analysis | — |
8-K | Feb 27, 2026 | — | Analysis | — |
10-K | Feb 27, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 12, 2026 | — | — | |
8-K | Dec 1, 2025 | — | — | |
10-Q | Nov 7, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 8, 2025 | Jun 30, 2025 | — | |
10-Q | May 9, 2025 | Mar 31, 2025 | — | |
10-K | Feb 28, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 8, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 6, 2024 | Jun 30, 2024 | — | |
10-Q | May 10, 2024 | Mar 31, 2024 | — | |
10-K | Feb 29, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 8, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | — | |
10-Q | May 8, 2023 | Mar 31, 2023 | — | |
10-K | Mar 9, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 9, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 8, 2022 | Jun 30, 2022 | — | |
10-Q | May 10, 2022 | Mar 31, 2022 | — | |
10-K | Mar 15, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 1, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 6, 2021 | Jun 30, 2021 | — | |
10-Q | May 7, 2021 | Mar 31, 2021 | — |
Frequently Asked Questions
What are the latest ANIP SEC filings in 2026?
ANI PHARMACEUTICALS INC (ANIP) has filed a 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 7, 2025, an 8-K current report on April 7, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ANIP file its most recent 10-K annual report?
ANI PHARMACEUTICALS INC (ANIP) filed its most recent 10-K annual report on February 27, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ANIP 10-Q quarterly reports?
ANI PHARMACEUTICALS INC (ANIP)'s most recent 10-Q quarterly report was filed on November 7, 2025. SignalX displays every ANIP 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ANIP filed recently?
ANI PHARMACEUTICALS INC (ANIP)'s most recent 8-K was filed on April 7, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ANIP insider trading activity (Form 4)?
SignalX aggregates every ANIP Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ANIP file with the SEC?
ANI PHARMACEUTICALS INC (ANIP) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ANIP filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ANI PHARMACEUTICALS INC (ANIP).
What is ANIP's SEC CIK number?
ANI PHARMACEUTICALS INC (ANIP)'s SEC CIK (Central Index Key) number is 1023024. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1023024 to look up all ANIP filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ANIP return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from ANI PHARMACEUTICALS INC (ANIP) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of ANI PHARMACEUTICALS INC SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 53+ filings.